Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Holding DE:DUL?
Track your performance easily
DUL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.70 - €272.00
Previous Close€245
Volume0.00
Average Volume (3M)57.00
Market Cap
€31.82B
Enterprise Value€30.61B
Total Cash (Recent Filing)$2.62B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Oct 24, 2024EPS Estimate
-€0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,380,513
10 Day Avg. Volume5
30 Day Avg. Volume57
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-12250.00
Price to Sales (P/S)14.85
Price to Cash Flow (P/CF)70.10
P/FCF Ratio74.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.06
Enterprise Value/Gross Profit20.17
Enterprise Value/Ebitda297.27
Forecast
1Y Price Target
€280.94Price Target Upside14.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical DataVutrisiran shows a statistically significant impact on echocardiographic cardiac structure.
Commercial PotentialPositive feedback from key opinion leaders reinforces confidence in vutrisiran’s differentiated profile and the large commercial opportunity in ATTR-CM.
Management ConfidenceManagement is confident in Amvuttra’s positioning for first-line treatment and believes it is well-positioned to become the standard of care in ATTR-CM.
Bears Say
Insurance ReimbursementTwo branded drugs could be challenging to get insurance reimbursed, making the loss of exclusivity of Pfizer’s tafamidis an important date to note.
Market ProjectionsConsensus projections for vutrisiran likely need to come down significantly.
Pricing And Market ShareA high Amvuttra price (vs. stabilizers) in ATTR-CM may negatively impact Amvuttra market share, due to potential payer preference for lower-cost therapies.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.38% Insiders
44.81% Mutual Funds
0.08% Other Institutional Investors
39.55% Public Companies and
Individual Investors
DUL FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was €132.70 and its highest was €272.00 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 24, 2024 which is in 13 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -€0.118 earnings per share for the quarter, beating the consensus estimate of -€0.971 by €0.853.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -€0.85.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 128,380,510 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -€0.118 in its last earnings report, beating expectations of -€0.971. Following the earnings report the stock price went up 3.399%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 919M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€280.94 (14.67% Upside)
€280.94 (14.67% Upside)
Blogger Sentiment
Bullish
DE:DUL Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.85%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
DUL Company Deck
---
DUL Earnings Call
Q2 2024
0:00 / 0:00
---
DUL Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
DUL Stock 12 Month Forecast
Average Price Target
€280.94
▲(14.67% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Incyte
―
Best Analysts Covering DUL
1 Year
1 Year Success Rate
18/22 ratings generated profit
1 Year Average Return
+23.36%
reiterated a buy rating last month
Copying Paul Matteis's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +23.36% per trade.
---